natgillin/translations-raw huggingface dataset:
If this happens, do not drive or operate machines. 
Če se to zgodi, ne vozite in ne upravljajte s stroji.
Medicinal products listed above are not repeated in Table 1 and 2 unless specific interaction data is available. 
Zgornja zdravila niso ponovno navedena v tabelah 1 in 2, razen če so na razpolago posebni podatki o medsebojnem delovanju.
• if you are taking any of the following medicines: 
• če jemljete katero od zdravil:
Please see ‘Warnings and precautions' in Section 2 above. 
Prosimo, glejte 'Opozorila in previdnostni ukrepi' v poglavju 2.
Interaction via effects on transport proteins cannot be excluded. 
Interakcije preko učinkov na transportne beljakovine ne moremo izključiti.
Refer also to sections 4.2 and 4.3. 
Prosimo preberite tudi poglavji 4.2 ter 4.3.
The main role of the immune system is to protect you from infections. 
Glavna vloga vašega imunskega sistema je, da vas zaščiti pred okužbo.
The pharmacokinetic parameters in the second study were comparable. 
Parametri farmakokinetike v drugi študiji so bili primerljivi.
In more than a half of the reported cases, treatment with PIs was continued or re-introduced if treatment had been discontinued. 
V več kot polovici poročanih primerov so zdravljenje s PI nadaljevali ali ponovno uvedli, če je bilo zdravljenje prekinjeno.
You may still get infections or other illnesses related to HIV. 
Še vedno lahko dobite okužbe ali druge bolezni, povezane z virusom HIV.
When to take 
Kdaj vzeti
A causal relationship has been evoked, although the mechanism of action has not been elucidated. 
Verjetno obstaja vzročna povezava, čeprav mehanizem delovanja ni pojasnjen.
How often they happen is not known: 
Kako pogosto se pojavljajo, ni znano.
The appropriate doses for this combination, with respect to efficacy and safety, have not been established. 
Ustreznih odmerkov za to kombinacijo glede na učinkovitost in varnost niso ugotovili.
You may need to have blood tests to check how your liver is working. 
Mogoče boste morali narediti krvne teste, da bodo preverili delovanje vaših jeter.
Your doctor will monitor how this medicine works for you. 
Zdravnik bo spremljal, kako zdravilo deluje na vas.
None of these substitutions was either necessary or sufficient for resistance. 
Nobena od teh substitucij ni bila ne nujna ne zadostna za pojav rezistence.
The clinical significance of this finding is unknown. 
Klinični pomen teh ugotovitev ni znan.
Acute haemolytic anaemia has been reported which in some cases was severe and progressed rapidly. 
Poročali so o akutni hemolitični anemiji, ki je bila v nekaterih primerih huda in je hitro napredovala.
Within studies, this effect is sustained also after prolonged periods of follow-up. 
Znotraj raziskav se ta učinek ohrani tudi po daljšem obdobju spremljanja.
This medicine contains lactose (type of sugar). 
To zdravilo vsebuje laktozo (vrsta sladkorja).
• if you are allergic to indinavir or any of the other ingredients of this medicine (listed in Section 6). 
• če ste alergični na indinavir ali katero koli sestavino tega zdravila (navedeno v poglavju 6)
• pain and difficulty moving shoulder. 
• bolečina in težave pri premikanju rame
• difficulty getting to sleep 
• težave s spanjem
• lower the amount of HIV in your body (your ‘viral load') 
• zmanjšati količino virusa HIV v telesu ('virusno obremenitev')
On rare occasions the muscle problems can be serious (rhabdomyolysis). 
V redkih primerih so težave z mišicami lahko resne (rabdomioliza).
Mothers should be instructed to discontinue breast feeding during treatment. 
Materam je treba naročiti, naj v času zdravljenja prekinejo z dojenjem.
For optimal absorption, CRIXIVAN should be administered without food but with water 1 hour before or 2 hours after a meal. 
Za optimalno absorpcijo se zdravila CRIXIVAN ne sme jemati s hrano, ampak z vodo eno uro pred obrokom ali dve uri po njem.
In general, however, higher levels of resistance resulted from the co-expression of greater numbers of substitutions at the eleven identified positions. 
Na splošno je višjo stopnjo rezistence sprožila koekspresija večjega števila substitucij na enajstih ugotovljenih mestih.
Midazolam (parenteral) 
Midazolam (parenteralni)
Currently available data in children above the age of 4 years are described in sections 4.8, 5.1, and 5.2. 
Podatki, ki so trenutno na voljo za otroke, starejše od 4 let, so podani v poglavjih 4.8, 5.1 in 5.2.
Use the lowest possible dose of atorvastatin with careful monitoring. 
Uporabite najmanjši mogoči odmerek atorvastatina in skrbno spremljajte.
During pregnancy, it has been demonstrated that the systemic exposure of indinavir is relevantly decreased (PACTG 358. 
Dokazano je, da je med nosečnostjo sistemska izpostavljenost indinavirja ustrezno znižana (PACTG 358.
HIV is spread by blood or sexual contact with a person with HIV. 
Virus HIV se prenaša s krvjo ali s spolnim stikom z osebo, okuženo z virusom HIV.
• If you are pregnant, think you may be pregnant or are planning to have a baby, only take CRIXIVAN if your doctor decides it is clearly necessary. 
• Če ste noseči, menite, da bi lahko bili noseči ali načrtujete zanositev, lahko zdravilo CRIXIVAN jemljete le, če zdravnik odloči, da je to nujno potrebno.
• lower the risk that you get illnesses related to HIV 
• zmanjšati tveganje za pojav bolezni, povezanih z virusom HIV,
Some of these events were associated with mild elevation of serum creatinine. 
Nekaj teh dogodkov je bilo povezanih z rahlim zvišanjem serumskega kreatinina.
This happens in some people with advanced HIV infection (AIDS) and who have had HIV related infections before. 
To se zgodi pri nekaterih bolnikih z napredovano okužbo s HIV (AIDS), ki so že imeli okužbe, povezane s HIV.
This is called combination antiretroviral therapy. 
To se imenuje kombinirano antiretrovirusno zdravljenje.
• low red blood cell count 
• nizko število rdečih krvnih celic
No specific dose recommendation can be given. 
Ni posebnih priporočil za odmerjanje.
• feeling numb or unusual feeling of the skin. 
• občutek odrevenelosti ali nenavaden občutek na koži
The mean half-life of indinavir increased to approximately 2.8 hours. 
Povprečen razpolovni čas indinavirja je narasel na približno 2,8 ur.
• Do not stop taking CRIXIVAN without talking to your doctor. 
• Ne prenehajte z jemanjem zdravila CRIXIVAN, ne da bi se o tem posvetovali z zdravnikom.
Eighteen patients completed the study to week 48. 
18 bolnikov je študijo končalo do 48. tedna.
• raise your CD4 (T) cell count. 
• povečati število CD4 (T) celic.
• allergies 
• alergija
The recommended doses are: 
Priporočeni odmerki so:
Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach. 
Formulacije indinavirja in didanozina, ki vsebujejo pufer, je treba dajati v razmiku vsaj ene ure, na prazen želodec.
• altered taste sensations 
• spremenjen okus
Indinavir was rapidly eliminated with a half-life of 1.8 hours. 
Indinavir se je izločal hitro z razpolovnim časom 1,8 ure.
• blood in your urine. 
• kri v urinu
If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment. 
Če opazite kakršne koli simptome okužbe ali druge simptome, kot so oslabelost mišic, šibkost, ki se začne v dlaneh in stopalih in se širi navzgor proti trupu telesa, palpitacije, tremor ali hiperaktivnost, prosimo takoj obvestite zdravnika, ki bo poskrbel za primerno zdravljenje.
The pharmacokinetics of indinavir in these 11 patients at 6 weeks postpartum were generally similar to those observed in non-pregnant patients in another study (see section 4.6). 
Farmakokinetika indinavirja pri teh 11 bolnicah je bila 6 tednov po porodu na splošno podobna kot pri ne nosečih bolnicah v drugi raziskavi (glejte poglavje 4.6 ).
Interaction unknown. 
Interakcija ni znana.
There are no data to suggest that indinavir affects the ability to drive and use machines. 
Nimamo podatkov, ki bi nakazovali, da indinavir vpliva na sposobnost vožnje in upravljanja s stroji.
• severe pain, tenderness or weakness in your muscles - this is more likely to happen if you are taking cholesterol-lowering medicines called ‘statins' (such as simvastatin). 
• huda bolečina, občutljivost ali šibkost v mišicah - to je bolj verjetno, če jemljete zdravila za zniževanje holesterola, imenovana 'statini' (kot je simvastatin).
Many of these adverse reactions were also identified as common pre-existing or frequently occurring medical conditions in this population. 
Za veliko teh neželenih učinkov so ugotovili, da so ali pogosta že obstoječa stanja ali pogosta obolenja te populacije.
There are no data available regarding potential effects of CRIXIVAN treatment on male or female fertility. 
Ni podatkov o potencialnih učinkih zdravljenja z zdravilom CRIXIVAN na plodnost pri moških ali ženskah.
So you still need to keep seeing your doctor while you are taking CRIXIVAN. 
Zato je še vedno potrebno, da obiskujete zdravnika, medtem ko jemljete zdravilo CRIXIVAN.
Distribution Indinavir was not highly bound to human plasma proteins (39 % unbound). 
Porazdelitev Indinavir se ni močno vezal na plazemske beljakovine (39 % nevezanega).
Children and adolescents CRIXIVAN is not recommended in children under the age of 18 years. 
Otroci in mladostniki Uporaba zdravila CRIXIVAN pri otrocih in mladostnikih do 18. leta starosti ni priporočljiva.
On the basis of current pharmacodynamic data, indinavir must be used in combination with other antiretroviral agents. 
Na podlagi trenutnih farmakodinamskih podatkov moramo indinavir uporabljati v kombinaciji z drugimi protiretrovirusnimi zdravili.
This will help lower the risk of you getting kidney stones. 
S tem se zmanjša možnost nastanka ledvičnih kamnov.
Please see ‘Do not take CRIXIVAN' and ‘Do not take either CRIXIVAN or ritonavir' above under Section 2 for an important list of medicines that you must not combine with CRIXIVAN. 
Prosimo, glejte podpoglavji 'Ne jemljite zdravila CRIXIVAN' in 'Ne jemljite niti zdravila CRIXIVAN niti ritonavirja' v poglavju 2 za pomemben seznam zdravil, ki jih ne smete kombinirati z zdravilom CRIXIVAN.
• signs of infection - this may be a previous infection which comes back soon after anti-HIV treatment is started. 
• simptomi okužbe - to je lahko predhodna okužba, ki se ponovi, ko se začne zdravljenje proti HIV.
isolated asymptomatic hyperbilirubinaemia, increased ALT and AST 
izolirana asimptomatična hiperbilirubinemija, povečani ALT in AST
• It is recommended that women with HIV do not breast-feed. 
• Priporočeno je, naj ženske, okužene z virusom HIV, ne dojijo.
This is to stop HIV being passed on to their baby. 
S tem se prepreči prenos virusa HIV na otroka.
Ritonavir is used for increasing the blood levels of CRIXIVAN or, less frequently and then at higher doses, for HIV treatment. 
Ritonavir se uporablja za zvišanje zdravila CRIXIVAN v krvi, ali manj pogosto in pri višjih odmerkih, za zdravljenje okužb s HIV.
Less than 20 % of indinavir is excreted renally. 
Manj kot 20 % indinavirja se izloča preko ledvic.
CRIXIVAN is used at the same time as other HIV treatments (antiretroviral medicines). 
Zdravilo CRIXIVAN se uporablja istočasno z drugimi HIV zdravili (protiretrovirusnimi zdravili).
There are also other side effects that you may get while taking this medicine such as increased bleeding in haemophiliacs, muscle problems, signs of infection, and bone problems. 
Obstajajo tudi drugi neželeni učinki, ki jih lahko dobite v času jemanja zdravila, kot so povečano krvavljenje pri hemofilikih, težave z mišicami, znaki okužbe in težave s kostmi.
It is not known whether indinavir is excreted in human milk. 
Ni znano, ali se indinavir izloča v materino mleko.
Since CRIXIVAN must be taken at intervals of 8 hours, a schedule convenient for the patient should be developed. 
Ker je treba CRIXIVAN jemati v 8-urnih intervalih, je treba narediti načrt jemanja, ki je primeren za bolnika.
CsA levels require progressive dose adjustment using therapeutic medicinal product monitoring. 
Ravni CsA zahtevajo postopno prilagajanje odmerka ob spremljanju terapevtskih učinkov zdravila.
Talk to your doctor if you are going to take both CRIXIVAN and ritonavir. 
Pogovorite se z zdravnikom, če boste jemali obe zdravili, CRIXIVAN in ritonavir.
Indinavir did not have any mutagenic or genotoxic activity in studies with or without metabolic activation. 
Indinavir ni imel nikakršne mutagene ali genotoksične aktivnosti v raziskavah s presnovno aktivacijo ali brez nje.
There are no data concerning the penetration of indinavir into the central nervous system in humans. 
Glede prehoda indinavirja v centralni živčni sistem pri človeku ni podatkov.
Autoimmune disorders may occur many months after the start of treatment. 
Avtoimune bolezni se lahko pojavijo več mesecev po začetku zdravljenja.
• tacrolimus, ciclosporin - used mainly after organ transplantation 
• takrolimus, ciklosporin - večinoma se uporablja po presaditvi organa
Haemophiliac patients should therefore be made aware of the possibility of increased bleeding. 
Bolnike s hemofilijo je zato treba seznaniti z možnostjo povečanja pojava krvavitev.
Do not use this medicine after the expiry date which is stated on the bottle or carton after ‘EXP'. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki ali škatli poleg oznake "Uporabno do".
Very common (≥ 1/10); Common (≥ 1/100 to  1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥ 1/10,000 to  1/1,000); Very rare (< 1/10,000); not known (cannot be estimated from the available data). 
Zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
If you notice bleeding or if you feel weak, talk to your doctor straight away. 
Če opazite krvavitve ali se počutite šibki, se takoj posvetujte z zdravnikom.
This includes medicines obtained without a prescription, including herbal medicines. 
To velja tudi za zdravila, ki ste jih dobili brez recepta in zdravila rastlinskega izvora.
No significant difference in exposure was seen when the regimen was given with a high-fat meal. 
Nobenih pomembnih razlik v izpostavljenosti ni bilo opaziti pri dajanju zdravila z obroki z visoko vsebnostjo maščob.
The relevance of the findings to humans is likely limited. 
Povezava teh odkritij s človekom je precej omejena.
HIV Transmission 
Prenos virusa HIV
Combination not recommended 
Kombinacija ni priporočljiva.
It is not known whether CRIXIVAN is harmful to an unborn baby when taken by a pregnant woman. 
Ni znano, ali je zdravilo CRIXIVAN, če ga jemlje noseča ženska, škodljivo za nerojenega otroka.
CRIXIVAN helps to: 
Zdravilo CRIXIVAN pomaga:
• oral contraceptive medicines (‘The Pill') containing norethindrone or ethinyl estradiol 
• zdravila za kontracepcijo ('tabletka'), ki vsebujejo noretindron ali etinilestradiol
Common (affects less than 1 in 10 people): 
Pogosti (pojavijo se pri manj kot 1 od 10 bolnikov):
Also look at the Package Leaflet for ritonavir. 
Prav tako poglejte navodilo za uporabo za ritonavir.
Dose adjustment for midazolam should be considered, especially if more than a single dose of midazolam is administered. 
Pri midazolamu je treba razmisliti o prilagajanju odmerka, predvsem če se da več kot enkratni odmerek midazolama.
• Swallow the capsules whole with a drink of water, skimmed or low fat milk, juice, tea or coffee. 
• Pogoltnite cele kapsule skupaj z vodo, posnetim mlekom ali mlekom z nizko vsebnostjo maščob, sokom, čajem ali kavo.
If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered. 
Če pri takih bolnikih pride do dokazanega poslabšanja jetrne bolezni, je treba razmisliti o začasni ali dokončni prekinitvi zdravljenja.
Do not take CRIXIVAN: 
Ne jemljite zdravila CRIXIVAN:
Dose adjustment of warfarin may be required. 
Morda bo potrebna prilagoditev odmerka varfarina.
It is not known whether indinavir is dialyzable by peritoneal or haemodialysis. 
Ni znano, ali se indinavir dializira s peritonealno dializo ali hemodializo.
CRIXIVAN may not do these things in all patients. 
Možno pa je, da zdravilo CRIXIVAN teh učinkov nima pri vseh bolnikih.
If you notice any of these signs, talk to your doctor. 
Če opazite katerega od teh znakov, se posvetujte z zdravnikom.
Data from a steady state study in healthy volunteers indicate that there is a diurnal variation in the pharmacokinetics of indinavir. 
Podatki iz raziskave pri zdravih prostovoljcih v stanju dinamičnega ravnovesja kažejo na to, da prihaja do dnevnih sprememb v farmakokinetiki indinavirja.
Desiccant should not be removed from the container. 
Sušilnega sredstva ne smete odstraniti iz vsebnika.
Other medicines and CRIXIVAN 
Druga zdravila in zdravilo CRIXIVAN
If no alternative treatment is available, use with careful monitoring. 
Če drugo zdravljenje ni na voljo, skrbno spremljajte potek.
At least eleven amino acid sites in the protease have been associated with indinavir resistance: L10, K20, L24, M46, I54, L63, I64, A71, V82, I84, and L90. 
Odkrili so najmanj enajst aminokislinskih mest na proteazi, ki so povezana z rezistenco na indinavir: L10, K20, L24, M46, I54, L63, I64, A71, V82, I84 in L90.
In rats and rabbits, no effects on embryonic/foetal survival or foetal weights were observed. 
Pri podganah in kuncih niso opazili nobenih učinkov na embrionalno/fetalno preživetje ali na maso ploda.
The risk of you having bone problems is higher if you: - drink alcohol - have a high body mass index - have an immune system that is very weak - have been taking corticosteroids at the same time as CRIXIVAN - take combination antiretroviral therapy for a long time. 
Tveganje, da boste imeli težave s kostmi, je večja, če: - pijete alkohol - imate visok indeks telesne mase - imate zelo oslabljen imunski sistem - ste prejemali kortikosteroide istočasno z zdravilom CRIXIVAN - ste dalj časa na kombiniranem protiretrovirusnem zdravljenju
• The active substance is indinavir. 
• Zdravilna učinkovina je indinavir.
• Do not crush or chew the capsules. 
• Kapsul ne drobite ali žvečite.
• feeling dizzy, weak or tired. 
• občutek vrtoglavice, oslabelost ali utrujenost
• midazolam (by injection) - used for acute fits (seizures) and to send patients to sleep before some medical procedures 
• midazolam (dan z injekcijo) - za zdravljenje akutnih napadov krčev in uspavanje bolnikov pred nekaterimi medicinskimi posegi
Tell your doctor, pharmacist or nurse if you are taking, have recently taken, or might take any other medicines. 
Obvestite svojega zdravnika, farmacevta ali medicinsko sestro, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
In addition, when CRIXIVAN is given at the same time as the medicine ritonavir: Do not take either CRIXIVAN or ritonavir: 
Poleg tega, ko zdravilo CRIXIVAN jemljete istočasno kot zdravilo ritonavir: Ne jemljite niti zdravila CRIXIVAN niti ritonavirja:
Most patients continued treatment with CRIXIVAN without dose reduction and bilirubin values gradually declined toward baseline. 
Večina bolnikov je nadaljevala z zdravljenjem z zdravilom CRIXIVAN, ne da bi jim zmanjšali odmerek, koncentracija bilirubina pa se je počasi zmanjševala proti osnovni vrednosti.
No formal interaction study has been performed. 
Uradnih študij medsebojnega delovanja niso izvedli.
It should be noted that the decrease in suppression of viral RNA levels was seen more frequently when therapy with indinavir was initiated at doses lower than the recommended oral dose of 2.4 g/day. 
Treba je opozoriti še na to, da je do zmanjšanja supresije ravni virusne RNA prišlo pogosteje, kadar so zdravljenje z indinavirjem začeli z odmerki, nižjimi od priporočenega peroralnega odmerka 2,4 g na dan.
The resulting immature particles are noninfectious and are incapable of establishing new cycles of infection. 
Nastanejo nezreli virusni delci, ki niso kužni in ne morejo začeti novega kroga okužbe.
Studies in rats indicated that uptake into brain tissue was limited, distribution into and out of the lymphatic system was rapid, and excretion into the milk of lactating rats was extensive. 
Raziskave pri podganah so pokazale omejen privzem v možgane, hitro porazdelitev v limfatični sistem in iz njega ter obsežno izločanje v mleko doječih podgan.
The observed amino acid substitutions appeared to accumulate sequentially and in no consistent order, probably as a result of ongoing viral replication. 
Zdelo se je, da se aminokislinske substitucije kopičijo zaporedno in brez doslednega reda, verjetno zaradi stalno potekajočega virusnega podvajanja.
Dose adjustment should be considered based on the patient's clinical response to methadone therapy. 
O prilagoditvi odmerka je treba razmisliti glede na bolnikov klinični odziv na zdravljenje z metadonom.
Formulation with buffer 
Formulacija s pufrom
Developmental toxicity studies were performed in rats, rabbits and dogs (at doses which produced systemic exposures comparable to or slightly greater than human exposure) and revealed no evidence of teratogenicity. 
Raziskave o toksičnih učinkih na razvoj so opravili na podganah, kuncih in psih (z odmerki, ki povzročijo sistemsko izpostavljenost, primerljivo ali rahlo večjo od izpostavljenosti pri človeku) in niso odkrili dokazov za teratogenost.
There is no significant effect of unboosted indinavir on methadone AUC (see Table 1 above). 
Pomembnega učinka neokrepljenega indinavirja na AUC metadona ni (glejte zgornjo tabelo 1).
To ensure adequate hydration, it is recommended that adults drink at least 1.5 litres of liquids during the course of 24 hours. 
Za zagotovitev zadostne količine vode v telesu priporočamo, da odrasel bolnik v 24-ih urah popije vsaj 1,5 l tekočine.
• severe skin reactions 
• hude kožne reakcije
CRIXIVAN can affect the way some other medicines work. 
Zdravilo CRIXIVAN lahko vpliva na delovanje drugih zdravil.
Indinavir did not significantly inhibit the eukaryotic proteases human renin, human cathepsin D, human elastase, and human factor Xa. 
Indinavir ni pomembno inhibiral evkariontskih proteaz: humanega renina, humanega katepsina D, humane elastaze in humanega faktorja Xa.
What CRIXIVAN is and what it is used for 
Kaj je zdravilo CRIXIVAN in za kaj ga uporabljamo
Many of the protease amino acid substitutions reported to be associated with resistance to ritonavir and saquinavir were also associated with resistance to indinavir. 
Veliko proteaznih aminokislinskih substitucij, o katerih so poročali, da so povezane z rezistenco na ritonavir in sakvinavir, je bilo povezanih tudi z rezistenco na indinavir.
The safety and efficacy of CRIXIVAN in children under the age of 4 years have not been established (see sections 5.1 and 5.2). 
Varnost in učinkovitost zdravila CRIXIVAN pri otrocih, mlajših od 4 let, nista bili dokazani (glejte poglavji 5.1 in 5.2).
Atazanavir as well as indinavir are associated with indirect (unconjugated) hyperbilirubinemia due to inhibition of UDP-glucuronosyltransferase (UGT). 
Atazanavir kot tudi indinavir sta povezana z indirektno (nekonjugirano) hiperbilirubinemijo zaradi inhibicije UDP-glukuronoziltransferaze (UGT).
• It is important for adults to drink at least 1.5 litres of liquid each day while taking CRIXIVAN. 
• Za odrasle je pomembno, da med jemanjem zdravila CRIXIVAN vsak dan popijejo vsaj
Asymptomatic pyuria of unknown etiology was noted in 10.9 % (6/55) of paediatric patients who received CRIXIVAN. 
Asimptomatsko piurijo neznanega izvora so opazili pri 10,9 % (6/55) pediatričnih bolnikov, ki so prejemali zdravilo CRIXIVAN.
Do not take CRIXIVAN if you are taking or have recently taken any of these medicines. 
Ne jemljite zdravila CRIXIVAN, če jemljete ali ste pred kratkim jemali katero koli od naštetih zdravil.